The established AML-iPSC model showed multiple paths to differentiate, in which the hematopoietic lineage differentiation from the reprogrammed human myeloid iPSCs regained tumorigenicity; nevertheless, the nonhematopoietic lineages, such as cardiomyocytes derived from the same AML-iPSCs lost their BCR-ABL dependent cancerous features (46, 47). Here, ABL1 is linked to acute myeloid leukemia.